<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1729-519X</journal-id>
<journal-title><![CDATA[Revista Habanera de Ciencias Médicas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev haban cienc méd]]></abbrev-journal-title>
<issn>1729-519X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de la Habana]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1729-519X2022000300004</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Enfermedad de Alzheimer: actualización en su prevención, diagnóstico y tratamiento]]></article-title>
<article-title xml:lang="en"><![CDATA[Alzheimer's disease: update in prevention, diagnosis and treatment]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llibre-Rodriguez]]></surname>
<given-names><![CDATA[Juan de Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gutiérrez Herrera]]></surname>
<given-names><![CDATA[Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guerra Hernández]]></surname>
<given-names><![CDATA[Milagros A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de La Habana  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Autónoma de Nuevo León  ]]></institution>
<addr-line><![CDATA[Nuevo León ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Sanatorio &#8220;San Juan de Dios&#8221;  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>21</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1729-519X2022000300004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1729-519X2022000300004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1729-519X2022000300004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  En el mundo, 55 millones de personas viven con demencia. Se estima que este número se incrementará a 82 millones en 2030 y 152 millones en 2050, a menos que se implementen intervenciones que permitan su prevención, retardar su comienzo, enlentecer o detener su progresión.  Objetivo:  Actualizar sobre los cambios recientes en la epidemiologia, diagnóstico y tratamiento de la enfermedad de Alzheimer.  Material y Métodos:  Revisión de la literatura sobre el tema, publicada entre el 1 de enero de 2010 y el 30 de diciembre de 2021, que incluyó las bases de datos (PubMed/MEDLINE, EMBASE, Lilacs, SciELO y Cochrane CENTRAL, utilizando los términos &#8220;Alzheimer&#8221;, OR &#8220;demencia&#8221;, OR &#8220;deterioro cognitivo&#8221;.  Desarrollo:  Los gobiernos deben prepararse para un tsunami de demanda de servicios de salud como resultado del envejecimiento de la población mundial, la mejora de los diagnósticos, incluidos los biomarcadores y los tratamientos farmacológicos emergentes. La detección oportuna del deterioro cognitivo, el diagnóstico causal y el manejo adecuado de la entidad nosológica es crucial.  Conclusiones:  Los sistemas de salud a nivel mundial deberían introducir evaluaciones de la función cognitiva para las personas mayores de 55 años, facilitados por la evolución en la ciencia de los biomarcadores, con la oportunidad de promover estrategias de reducción de riesgos. La existencia de factores de riesgo potencialmente modificables significa que la prevención de la demencia es posible mediante una estrategia de salud pública, con intervenciones claves que retrasen o desaceleren el comienzo del deterioro cognitivo y la demencia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Worldwide, nearly 55 million people are living with dementia. It is estimated that this number will reach nearly 82 million in 2030 and over 152 million in 2050, unless the risk factors are identified and interventions are implemented to prevent, delay the onset, and slow or stop its progression.  Objective:  To provide an update on recent changes in the epidemiology, diagnosis and treatment of Alzheimer's disease.  Material and Methods:  Bibliographic review of the literature on this subject published between January 1, 2012 and December 30, 2021 in PubMed/MEDLINE, EMBASE Lilacs, SciELO and Cochrane CENTRAL databases, using the terms " Alzheimer&#8221;, OR &#8220;dementia&#8221;, OR &#8220;cognitive impairment&#8221;.  Results:  The governments must prepare for a tsunami of demands for health services as a result of the world population aging and improve the diagnoses, including biomarkers and emerging pharmacological treatments. The timely detection of cognitive impairment, and the causal diagnosis and proper management of the nosological entity is crucial.  Conclusions:  The health systems should introduce annual neurocognitive assessments on a global level for people over 55 years of age, facilitated by the development of biomarker science, with the opportunity to promote risk reduction strategies. The existence of potentially modifiable risk factors means that dementia can be prevented through the implementation of a public health strategy with key interventions that delay or slow down the onset of cognitive impairment and dementia.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Demencia]]></kwd>
<kwd lng="es"><![CDATA[enfermedad de Alzheimer]]></kwd>
<kwd lng="es"><![CDATA[deterioro cognitivo]]></kwd>
<kwd lng="es"><![CDATA[prevención]]></kwd>
<kwd lng="es"><![CDATA[biomarcadores]]></kwd>
<kwd lng="en"><![CDATA[Dementia]]></kwd>
<kwd lng="en"><![CDATA[Alzheimer's disease]]></kwd>
<kwd lng="en"><![CDATA[cognitive impairment]]></kwd>
<kwd lng="en"><![CDATA[prevention]]></kwd>
<kwd lng="en"><![CDATA[biomarkers]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gauthier]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rosa Neto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Morais]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Webster]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[World Alzheimer Report 2021: Journey through the diagnosis of dementia]]></source>
<year>2021</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Alzheimer's Disease International]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsao]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aday]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Almarzooq]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beaton]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart Disease and Stroke Statistics-2022 Update A Report From the American Heart Association]]></article-title>
<source><![CDATA[Circulación]]></source>
<year>2022</year>
<volume>145</volume>
<page-range>153-639</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liberati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tetzlaff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preferred reporting items for systematic reviews and meta-analyses The PRISMA statement]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2009</year>
<volume>339</volume>
<page-range>332-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheltens]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[De Strooper]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kivipelto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Holstege]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chételat]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Teunissen]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alzheimer's disease]]></article-title>
<collab>t al</collab>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<page-range>1577-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Plan de acción mundial sobre la respuesta de salud pública a la demencia 2017-2025]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[Organización Mundial de la Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<collab>GBD 2019 Dementia Forecasting Collaborators</collab>
<article-title xml:lang=""><![CDATA[Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019]]></article-title>
<source><![CDATA[Lancet Public Health]]></source>
<year>2022</year>
<volume>S2468-2667</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>00249-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JLlibre Rodríguez JJ]]></surname>
<given-names><![CDATA[Valhuerdi A]]></given-names>
</name>
<name>
<surname><![CDATA[López AM]]></surname>
<given-names><![CDATA[Noriega]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cuba´s Aging and Alzheimer Longitudinal Study]]></article-title>
<source><![CDATA[MEDICC Review]]></source>
<year>2017</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Livingston]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Huntley]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sommerlad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ames]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ballard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Banerjee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dementia prevention, intervention, and care 2020 report of the Lancet Commission]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>396</volume>
<page-range>413-26</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loy]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Schofield]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetics of dementia]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>383</volume>
<numero>9919</numero>
<issue>9919</issue>
<page-range>828-40</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Kanekiyo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apolipoprotein E and Alzheimer disease risk, mechanisms and therapy. Nat. Rev]]></article-title>
<source><![CDATA[Neurol]]></source>
<year>2013</year>
<volume>9</volume>
<page-range>106-18</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDade]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Libre Guerra]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Holtzman]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Randall]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The informed road map to prevention of Alzheimer Disease- a call to arms]]></article-title>
<source><![CDATA[Molecular Neurodegeneration]]></source>
<year>2021</year>
<volume>16</volume>
<numero>49</numero>
<issue>49</issue>
<page-range>2-19</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petersen]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practice guideline update summary mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2018</year>
<volume>90</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>126-35</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKhann]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Drachmann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Folstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>1984</year>
<volume>34</volume>
<page-range>939-44</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dubois]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Villain]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Frisoni]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Rabinovici]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Sabbagh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cappa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical diagnosis of Alzheimer's disease recommendations of the International Working Group]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2021</year>
<volume>20</volume>
<page-range>484-96</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Alzheimer´s Disease Clinical Spectrum Diagnosis and Management]]></article-title>
<source><![CDATA[Med Clin N Am]]></source>
<year>2019</year>
<volume>103</volume>
<page-range>263-93</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<collab>National Institute for Health and Care Excellence</collab>
<source><![CDATA[Dementia: assessment, management and support for people living with dementia and their carers (NG97)]]></source>
<year>2018</year>
<publisher-loc><![CDATA[EE UU ]]></publisher-loc>
<publisher-name><![CDATA[National Institute for Health and Care Excellence]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gauthier]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Patterson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chertkow]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4)]]></article-title>
<source><![CDATA[Can Geriatr J]]></source>
<year>2012</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>120-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[McShane]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lindesay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial secondary and post-hoc analyses]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2015</year>
<volume>14</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1171-81</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Grossberg]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination therapy for Alzheimer's disease]]></article-title>
<source><![CDATA[Drugs &amp; aging]]></source>
<year>2011</year>
<volume>28</volume>
<page-range>539-46</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salloway]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Farlow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McDade]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Clifford]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's Disease]]></article-title>
<collab>Llibre Guerra? JJ</collab>
<source><![CDATA[Nat Med]]></source>
<year>2021</year>
<volume>27</volume>
<page-range>1187-96</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cummings]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aisen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lemere]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Atri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sabbagh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Salloway]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aducanumab produced a clinically meaningful benefit in association with amyloid lowering]]></article-title>
<source><![CDATA[Alzheimers Res Ther]]></source>
<year>2021</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-98</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>Gramma</collab>
<source><![CDATA[Aprueban Registro Sanitario Condicional de NeuroEPO para el tratamiento del Alzheimer leve y moderado]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Granma ]]></publisher-loc>
<publisher-name><![CDATA[Secc. Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kivipelto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mangialasche]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Allegri]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Andrieu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[World-Wide FINGERS Network a global approach to risk reduction and prevention of dementia]]></article-title>
<source><![CDATA[Alzheimer&amp;apos;s and Dementia]]></source>
<year>2020</year>
<volume>16</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1078-94</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
